Oncotarget. Zoya N. Demidenko
Oncotarget. Zoya N. Demidenko
impact factor oncotarget Zoya Demidenko Dr. Zoya N. Demidenko Zoya N. Demidenko , Ph.D. is Executive Manager of the Oncotarget journal . Oncotarget publishes high-impact research papers of general interest and outstanding significance and novelty in all areas of biology and medicine: in translational, basic and clinical research including but not limited to cancer research, oncogenes, oncoproteins and tumor suppressors, signaling pathways as potential targets for therapeutic intervention, shared targets in different diseases (cancer, benign tumors, atherosclerosis, eukaryotic infections, metabolic syndrome and other age-related diseases), chemotherapy, and new therapeutic strategies. After earning her Ph.D. in molecular biology, Zoya was awarded a Fogarty post-doctoral Fellowship from the National Institutes of Health in Bethesda, MD. After successful completion of post-doctoral training, she continued her professional career at George Washington University and Albert Einstein School of Medicine . In 2005 she cofounded the startup company Oncotarget Inc. which is focused on the development of anti-aging and anti-cancer drugs. Her research interests include signal transduction, cell cycle and cellular senescence, and their pharmacological targeting. In 2009 she cofounded the publishing house Impact Journals which specializes in publishing scientific journals. In 2011 she was selected to be a Member of the National Association of Professional Women .
https://mcb.asm.org/content/23/3/1014.abstract
oncotarget impact factor
When people refer to modern medicine, precision plays one of the most important roles and human lives are directly dependent on it. Hence, any researches related to medicine are necessary to meet the top standards. The issue today is that any results of researches can be posted online and used as a reference without being precisely verified and validated. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this issue and decided to come up with an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The key principle of this journal is related to Altmetric scores that are used as a quality measure. That helps both readers and authors to verify publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication.” Oncotarget website demonstrates a complete publications list with corresponding scores higher than 100 as well as reports mentioned above. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it provides the necessary help to anyone, who has interest in oncology.
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This study was released back in 2018 by Oncotarget and completed by several experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study discusses “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The paper has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that majority of readers are aiming to understand the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Hence, the paper about melanoma, was used for citations in different news articles 69 times. Besides that, it was quoted in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This article has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a concise overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive useful scientific facts. Oncotarget is happy to have the ability to share with online readers this highly appreciated and top-quality information, that is trustworthy and reliable.
https://www.livercenter.pitt.edu/news/2019-02/dr-mongas-group-publishes-oncotarget
Welcome to oncotarget.net, a website about Oncotarget, a peer-reviewed open access research journal focusing on all topics surrounding cancer research. Oncotarget is published by Impact Journals of Orchard Park, New York. Impact Journals meets the standards established Wellcome Trust Publisher Requirements and is included on the Wellcome Trust List of Compliant Publishers. Oncotarget is proud to have multiple Nobel Prize winning members on its editorial board, in addition to editors who have won the Lasker Prize and other prestigious recognitions. The open-access model employed by Oncotarget allows for free dissemination of thoroughly vetted peer-reviewed research material to the general public, leading to bigger and more frequent scientific breakthroughs. Because of Oncotarget’s uniquely varied scope, the journal has consistently published research on a wide range of subject areas, allowing readers to access an unparalleled diversity of knowledge in only one publication. The founding editors of Oncotarget are Mikhail (Misha) Blagosklonny and Andrei Gudkov. Dr. Blagosklonny is well-known for his research in the field of aging, having published numerous papers on the subject. Mikhail is credited for advancing groundbreaking research of the drug Rapamycin, an anti-aging medicine that has shown to slow down the aging process. Having been featured in numerous publications on aging including a Scientific American article titled “A New Path to Longevity” (link: https://www.scientificamerican.com/article/a-new-path-to-longevity/), Mikhail continues to provide meaningfully important contributions to the scientific community. Dr. Blagosklonny can be followed on twitter @Blagosklonny and you can visit his website at www.mikhailblagosklonny.com.To get in touch with Oncotarget, please visit our website at www.oncotarget.com. The journal’s ISSN is 1949-2553 and is indexed and/or archived in PubMed, Scopus, PMC, and the Chan Zuckerberg Meta initiative.Follow us on Twitter @Oncotarget!www.twitter.com/oncotarget
impact factor oncotarget Zoya Demidenko Dr. Zoya N. Demidenko Zoya N. Demidenko , Ph.D. is Executive Manager of the Oncotarget journal . Oncotarget publishes high-impact research papers of general interest and outstanding significance and novelty in all areas of biology and medicine: in translational, basic and clinical research including but not limited to cancer research, oncogenes, oncoproteins and tumor suppressors, signaling pathways as potential targets for therapeutic intervention, shared targets in different diseases (cancer, benign tumors, atherosclerosis, eukaryotic infections, metabolic syndrome and other age-related diseases), chemotherapy, and new therapeutic strategies. After earning her Ph.D. in molecular biology, Zoya was awarded a Fogarty post-doctoral Fellowship from the National Institutes of Health in Bethesda, MD. After successful completion of post-doctoral training, she continued her professional career at George Washington University and Albert Einstein School of Medicine . In 2005 she cofounded the startup company Oncotarget Inc. which is focused on the development of anti-aging and anti-cancer drugs. Her research interests include signal transduction, cell cycle and cellular senescence, and their pharmacological targeting. In 2009 she cofounded the publishing house Impact Journals which specializes in publishing scientific journals. In 2011 she was selected to be a Member of the National Association of Professional Women .
https://mcb.asm.org/content/23/3/1014.abstract
oncotarget impact factor
When people refer to modern medicine, precision plays one of the most important roles and human lives are directly dependent on it. Hence, any researches related to medicine are necessary to meet the top standards. The issue today is that any results of researches can be posted online and used as a reference without being precisely verified and validated. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this issue and decided to come up with an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The key principle of this journal is related to Altmetric scores that are used as a quality measure. That helps both readers and authors to verify publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication.” Oncotarget website demonstrates a complete publications list with corresponding scores higher than 100 as well as reports mentioned above. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it provides the necessary help to anyone, who has interest in oncology.
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This study was released back in 2018 by Oncotarget and completed by several experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study discusses “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The paper has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that majority of readers are aiming to understand the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Hence, the paper about melanoma, was used for citations in different news articles 69 times. Besides that, it was quoted in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This article has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a concise overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive useful scientific facts. Oncotarget is happy to have the ability to share with online readers this highly appreciated and top-quality information, that is trustworthy and reliable.
https://www.livercenter.pitt.edu/news/2019-02/dr-mongas-group-publishes-oncotarget
Comments
Post a Comment